Marketplace Donate Now Become a Member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Ottawa Marriott Hotel

Oct 17, 2017 7:00 AM - Oct 18, 2017 3:00 PM

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Back to Agenda

Session 4B: Market Access: Implications for and Piloting the Alignment of HTA and HC Reviews, and Comprehensive Economic and Trade Agreement (CETA)

Session Chair(s)

Keith McIntosh

Executive Director, Scientific & Regulatory Affairs, Innovative Medicines Canada, Canada

This session will focus on regulatory policies realted to market access. Attendees will learn about the approaches for HTA and regulatory approvals in Canada, and hear directly from Health Canada and CADTH about the work underway to streamline and coordinate these processes. The session will also examine the implication of CETA on pharmaceutical protection, including what benefits CETA may bring to Canadian consumers, patients and the economy.

Speaker(s)

Piloting the Alignment of HTA and HC Reviews

Kelly Lehman

Associate Director, Health Canada, Canada

Alexandra Chambers

Co-Presenter

Alexandra Chambers

Director, CADTH, Canada

Cheryl Cheung

The Implication of CETA on Pharmaceutical Patent Protection

Cheryl Cheung

Intellectual Property Counsel, Pharmascience, Canada

Have an account?